FDA sætter Regenxbios genterapier på pause efter hjernetumor hos barn; aktien falder
The FDA halted clinical trials of Regenxbio’s gene therapies RGX-111 and RGX-121 after a brain tumor was found in a child who received RGX-111. Shares dropped about 20% in early trading. The company is investigating whether the tumor is linked to the therapy. Regenxbio has not yet received the FDA’s full clinical hold letter.